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Abstract	
There remains an urgent need to identify existing drugs that might be suitable for treating 
patients suffering from COVID-19 infection.  Drugs rarely act at a single molecular target, with 
off target effects often being responsible for undesirable side effects and sometimes, beneficial 
synergy between targets for a specific illness. Off target activities have also led to blockbuster 
drugs in some cases, e.g. Viagra for erectile dysfunction and Minoxidil for male pattern hair loss. 
Drugs already in use or in clinical trials plus approved natural products constitute a rich resource 
for discovery of therapeutic agents that can be repurposed for existing and new conditions, based 
on the rationale that they have already been assessed for safety in man.  A key question then is 
how to rapidly and efficiently screen such compounds for activity against new pandemic 
pathogens such as COVID-19. Here we show how a fast and robust computational process can 
be used to screen large libraries of drugs and natural compounds to identify those that may 
inhibit the main protease of SARS-Cov-2 (3CL pro, Mpro). We show how the resulting shortlist 
of candidates with strongest binding affinities is highly enriched in compounds that have been 
independently identified as potential antivirals against COVID-19.  The top candidates also 
include a substantial number of drugs and natural products not previously identified as having 
potential COVID-19 activity, thereby providing additional targets for experimental validation. 
This in silico screening pipeline may also be useful for repurposing of existing drugs and 
discovery of new drug candidates against other medically important pathogens and for use in 
future pandemics. 
  
Introduction 
The devastating impact of the COVID-19 pandemic caused by SARS coronavirus-2 (SARS-
CoV-2) has stimulated unprecedented international activity to discover effective vaccines and 
drugs for this and other pathogenic coronaviruses such as SARS and MERS CoV.1-17  
Computational methods offer considerable promise for determining the affinities of small drug-
like molecules for SARS-Cov-2 protein targets. Recent papers in Science have reported the 
application of computational de novo drug design based on the structures of the SARS-Cov-2 
protease. 18, 19 Clearly, design of potent new drugs for coronaviruses is very important for future 
pandemic preparedness, given that the last three serious epidemics have been caused by 
coronaviruses. However, to make an impact on the current COVID-19 pandemic, it is only 
feasible to use drugs that are already registered (off label use), have been through at least phase 1 
clinical trials to establish initial human safety, or are approved natural products. Any COVID-19 
drug candidates identified in this way can then be used very quickly, as their safety and 
pharmacokinetics should be already well understood. Drugs that reduce viral replication 
primarily by targeting viral proteases and polymerases are classified as direct-acting antivirals 
and are the focus of the current work.  Other studies have explored host-targeted drugs that 
inhibit cellular functions required for viral replication and thereby inhibit SARS-Cov-2 infection, 
albeit with more potential for host side effects.20 
 The SARS-Cov-2 genome encodes > 20 proteins, many of which are potential antiviral 
drug targets (Figure 1). Two proteases (PL pro and 3CL pro) are essential for virus replication. 
These enzymes cleave the PP1A and PP1AB polyproteins into functional components. 3-
chymotrypsin-like protease (3CLpro, aka main protease, Mpro) catalytically self-cleaves a peptide 
bond between a glutamine at position P1 and a small amino acid (serine, alanine, or glycine) at 
position P1'. This protease corresponds to non-structural protein 5 (nsp5), the main protease in 
coronaviruses. 3CL protease is crucial to the processing of the coronavirus replicase polyprotein 
(P0C6U8), cleaving it at 11 conserved sites. 3CL protease employs a cys-his catalytic dyad in its 
active site where the cysteine sulfur is the nucleophile and the histidine imidazole ring is a 
general base. Very recent research has shown that strong Mpro inhibitors can substantially reduce 
SARS-Cov-2 virus titres, reduce weight loss and improve survival in mice,21 making Mpro a 
promising drug target for structure-based drug discovery. 
 
Figure 1. Virus entry and replicative cycle. Mpro produces non-structural proteins, Nsps, that are 
essential for assembly of the viral replication transcription complex needed for RNA synthesis. 
Inhibitors bind to Mpro, resulting in failure of virion assembly and inhibition of release of new 
functional virions. Adapted from Mengist et al.22 https://creativecommons.org/licenses/by/4.0/ 
 Computational methods can rapidly and efficiently identify candidate drugs for 
repurposing in pandemic situations where speed is of utmost importance. Here we used 
molecular docking followed by high throughput molecular dynamics simulations to prioritize 
from an initial large number of licensed or clinical trial drugs and natural products, a short list of 
the most promising candidates.  Molecular dynamics calculations were used to predict the 
optimal binding poses and binding energies for 84 of the top hits from docking-based virtual 
screening to the SARS-CoV-2 Mpro.  Finally, the top candidates were ranked based on binding 
affinity and novelty, for COVID-19 repurposing.  
Results and discussion 
The binding energies of the 84 top ranked ligands from the docking calculations are listed in 
Supplementary Table 1. The ten drugs with the tightest binding to Mpro are summarized in Table 
1, together with their GMXPBSA binding energies. The calculated binding energy of several of 
the antiviral drugs, namely, simeprevir, sofosbuvir, lopinavir, and ritonavir are very similar, 
within the uncertainties in calculated energies. Several of the top hits were antivirals identified in 
other in silico docking studies or wet-lab SARS-CoV-2 activity studies. This provides a degree 
of validation that our computational methods are appropriate and are yielding similar results to 
other published studies for some well-studied antiviral drugs. The web site DrugVirus.info 
provides a concise picture of the broad-spectrum antiviral activity of a range of drugs; a 
summary for four of the antiviral hits from our in silico screens is provided in Figure 2. 
  
Figure 2. Spectrum of antiviral activity and nature of assessment for four antiviral hit drugs. 
 
 Simeprevir was reported to be an inhibitor of the 3CLPro protease by Abhithaj et al.23  
They used a pharmacophore search followed by grid-based ligand docking (GLIDE, 
Schrodinger) and binding energy estimates from the MMGBSA method of -81.7 kcal/mol.   
However, they did not use MD to simulate the interaction of Simeprevir in the 3CLPro binding 
site. Similarly, Sofosbuvir was reported to be a strong inhibitor of the protease by Lo et al.24 
Using a Vero E6 cellular infection model, they also reported that Simeprevir was the only drug 
among their prioritized candidates that suppressed SARS-CoV-2 replication at below 10 μM. 
Dose-response studies showed that Simeprevir had  an EC50 of 4 μM, and CC50 of 20 μM, similar 
to Remdesivir in their experiments. 
Table 1. Binding energies of 10 top ranked predicted small molecule ligands to SARS-Cov-2 Mpro. 
ID Structure Description 
ΔGMMPBSA 
 (ΔGbind) 
(kcal/mol) 
C3809489  
Bemcentinib 
 
Inhibitor of the kinase 
domain of AXL 
receptor. 
-34.7±2.6 
(-30.7) 
C4291143 
PC786 
 
Respiratory syncytial 
virus (RSV) L protein 
polymerase inhibitor.  
-33.1±0.3 
(-29.2) 
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ID Structure Description 
ΔGMMPBSA 
 (ΔGbind) 
(kcal/mol) 
C787 
Montelukast 
 
Leukotriene receptor 
antagonist used with 
cortico-steroids for 
asthma therapy. 
-32.7±0.2 
(-20.6) 
C442 
Ergotamine 
 
Alpha-1 selective 
adrenergic agonist 
used in migraine 
treatment. 
-31.5±0.3 
(-28.7) 
D06290 
Simeprevir 
 
Hepatitis C virus 
(HCV) NS3/4A 
protease inhibitor.  
-31.4±0.2 
(-29.2) 
D08934 
Sofosbuvir 
 
Nucleotide prodrug 
and HCV NS5B 
polymerase inhibitor 
-31.0±0.5 
(-22.8) 
D01601 
Lopinavir 
 
Antiretroviral 
protease inhibitor for 
treatment of HIV-1  
-30.7±0.3 
(-20.4) 
D00503 
Ritonavir 
 
Peptidomimetic 
inhibitor of HIV-1 
and HIV-2 proteases 
-30.5±0.5 
(-21.3) 
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ID Structure Description 
ΔGMMPBSA 
 (ΔGbind) 
(kcal/mol) 
C2105887 
Mergocriptine 
 
Synthetic ergot 
derivative, dopamine 
receptor agonist. 
-30.0±0.3 
(-17.9) 
D14761 
Remdesivir 
 
Viral RNA-dependent 
RNA polymerase 
inhibitor. 
-30.0±0.2 
(-27.1) 
 
 The potential protease inhibition properties of Lopinavir and Ritonavir were reported by 
Bolcato et al., who used supervised MD to calculate the trajectories of the ligands in the protease 
binding site.25 Costanzo and colleagues likewise reported high protease binding for these two 
antiviral drugs.26 They also reported updates on experimental drugs successfully employed in the 
treatment of the disease caused by SARS-CoV-2 coronavirus. Patient recovery has been reported 
after treatment with lopinavir/ritonavir (used to treat HIV infection) in combination with the anti-
flu drug oseltamivir. Muralidharan et al. also used AutoDock (another docking program similar 
to Vina produced by the Scripps group) followed by MD simulations using the Generalised 
Amber Force Field (GAFF) in Amber16 to screen for repurposed drugs27 They reported 
AutoDock binding energies for lopinavir, oseltamivir and ritonavir of −4.1 kcal/mol, 
−4.65 kcal/mol, −5.11 kcal/mol, respectively but did not provide the binding energies from the 
MD calculations.  The best-known antiviral drug, which has been the subject of several clinical 
trials for COVID-19, is Remdesivir.28 The potential inhibition of the protease by this drug has 
been reported by several computational screening studies.  For example, Al-Khafaji and 
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colleagues reported a combined computational docking and MD study of a range of antiviral 
drugs to the viral protease.29 They calculated a binding energy for remdesivir of −65.19 kcal/mol 
from a GROMACS simulation and a MMGBSA binding energy calculation. Beck et al. reported a 
Kd for binding of remdesivir to 3CLPro of 113 nM using a deep learning model. Liu et al 
reported an in vitro assay that exploited the pronounced cytopathic effects of SAR-Cov-2 on 
Vero cells and the ability of a range of antiviral drugs to protect cells against the virus.30 In their 
assay, Remdesivir exhibited an IC50 of 2.5µM and CC50 of 175µM, while Sofosbuvir,  Lopinavir 
and Ritonavir were inactive. Similarly, Ma et al. reported a fluorescence resonance energy 
transfer (FRET)- based enzymatic assay for the SARS-CoV-2 Mpro and applied it to screening a 
library of protease inhibitors.31 In their assay, Simeprivir exhibited an IC50 of 14±3 µM. 
 The most interesting potential protease inhibitors from our study are the ergot alkaloids 
ergotamine, mergocriptine, the thrombopoietin receptor agonist eltrombopag (ranked 13 with 
ΔGMMPBSA=–28.2 kcal/mol, see Supplementary Table 1), bemcentinib, PC786, and montelukast. 
These drugs were predicted to have better binding energies than the antiviral drugs discussed 
above and have a higher degree of novelty. 
Ergot drugs 
Gurung et al. reported potential binding of ergotamine to the SAR-Cov-2 main protease in a 
preprint.32 The employed AutoDock Vina but without subsequent MD simulation of the 
complex. They reported the binding energy as −9.4 kcal/mol for dihydroergotamine and -9.3 
kcal/mol for ergotamine. Mevada et al. also reported the in-silico estimates of the binding of 
ergotamine to the protease using AutoDock Vina for the virtual screening.33  They found the 
drug bound with an energy of -10.2 kcal/mol, calculated using Vina (no subsequent MD 
simulation). Gul et al. used a similar docking approach, this time with MD simulation, and 
identified ergotamine and its derivatives dihydroergotamine and bromocriptine to have high 
binding affinity to SARS-Cov-2 3CLpro. Ergotamine is an alpha-1 selective adrenergic agonist 
and vasoconstrictor that had a high docking binding energy against SARS-Cov-2 Mpro of -8.6 
kcal/mol. Dihydroergotamine, the 9,10-alpha-dihydro derivative of ergotamine, showed similar 
high affinity of -8.6 kcal/mol and bromocryptine -9.2 kcal/mol. Ergotamine has also been 
predicted to bind tightly to the SARS-Cov-2 spike (S) protein.34  Figure 3 shows a LigPlot 
representation of the interactions of key functional groups in ergotamine and mergocriptine with 
protease active site residues. These are also listed in Supplementary Table 2 for reference. 
    
   
Figure 3. LigPlot (left) and hydrophobic protein surface representation (right) of the main 
interactions between Mpro and ergotamine (top) and mergocriptine (bottom). 
 
Montelukast 
Montelukast is a cysteinyl leukotriene receptor antagonist used treat asthma and allergic rhinitis. 
It reduces pulmonary responses to antigen, tissue eosinophilia and IL-5 expression in 
inflammatory cells and decreases elevated levels of IL-1β and IL8 in viral upper respiratory tract 
infections.35 Several computational have suggested putative binding to the terminal site of Mpro. 
Montelukast has been shown to inhibit at least one other protease, eosinophil protease.36 
 Mansoor and colleagues proposed that it could bind to Mpro on the basis of a simple 
molecular docking study.37 Wu et al also reported putative binding of montelukast to Mpro in a 
computational study using the same Internal Coordinate Mechanics modelling methods.38 No 
accurate binding affinities were reported in either study. Figure 4 shows a LigPlot representation 
of the interactions of key functional groups in montelukast with protease active site residues. 
These are also listed in Supplementary Table 2 for reference. 
  
Figure 4. LigPlot (left) and hydrophobic protein surface representation (right) of the main 
interactions between Mpro and montelukast. 
 
Bemcentinib 
Bemcentinib selectively inhibits AXL kinase activity, which blocks viral entry and enhances the 
antiviral type I interferon response. It’s in vitro activity against SARS-Cov-2 has been assessed by 
several groups. In a Vero cell assay, Liu et al reported 10-40% protection at 50µM.30 However, in 
an alternative assay using human  Huh7.5 cells,39 Bemcentinib exhibited an IC50 of 100nM and 
CC50 of 4.7µM. They also developed an assay in Vero cells and reported the IC50 was 470nM and 
CC50 was 1.6µM, considerably higher activity than that reported by Liu et al. As a result it is an 
investigational treatment for COVID-19 (www.clinicaltrialsregister.eu). Figure 5 shows a LigPlot 
representation of the interactions of key functional groups in bemcentinib with protease active site 
residues. These are also listed in Supplementary Table 2 for reference. 
  
Figure 5. LigPlot (left) and hydrophobic protein surface representation (right) of the main 
interactions between Mpro and bemcentinib. 
 
PC786 
PC786 targets the respiratory syncytial virus (RSV) L protein and is designed to be a topical 
inhalation treatment. There is very little published work on the SAR-Cov-2 efficacy or predicting 
binding affinity to Mpro. Panda and coworkers  reported a binding energy ΔGbind of PC786 of  
−179.79, tighter binding than calculated for lopinavir (−131.49 kJ/mol), using a combined docking 
and MD approach.40 Like our study, they employed Autodock Vina to dock a molecular library 
into the active site of Mpro, followed by MD simulation using GROMACS.  Figure 6 shows a 
LigPlot representation of the interactions of key functional groups in PC786 with protease active 
site residues. These are also listed in Supplementary Table 2 for reference. 
  
Figure 6. LigPlot (left) and hydrophobic protein surface representation (right) of the main 
interactions between Mpro and PC786. 
 
Other novel putative Mpro inhibitors from the short list of 84 drugs 
The predicted binding energies of the 84 drugs in the short list are summarized in Supplementary 
Table 1. We have also reviewed the literature for other in silico studies that have also identified 
some of these hit compounds as potential Mpro inhibitors and have listed experimental in vitro 
and in vivo results and clinical trials in progress for drugs on the list. Two thirds of the drugs on 
the list have been reported to be potential inhibitors of SARS-Cov-2 target proteins, largely Mpro 
but also RdRp, spike, helicase, human ACE2, 2’-O-methyltransferase nsp16/nsp10 complex, 
nsp1, PLpro, nsp3, and nsp12. Satisfyingly, those with the best predicted binding affinity from our 
study have also been of greatest interest clinically, with more in vitro assay results and clinical 
trials for drugs with the highest binding affinities. This suggests that our screening and MD 
simulation methods are sufficiently robust and accurate to identify drugs for repurposing against 
SARS-Cov-2 and, more broadly, other coronaviruses. The 33% of drugs in the hit list that have 
no reported studies are therefore also of interest as novel drugs for COVID-19. We discuss some 
of the more interesting and novel hit compounds with higher binding affinities. 
Eltrombopag 
Eltrombopag is a TPO agonist that acts at the transmembrane domain of its cognate receptor C-
Mpl via a histidine residue that occurs only in humans and apes. It scored highly in the docking 
studies, suggesting it could inhibit the 3CL protease and exhibit antiviral activity. Several other 
in silico screening studies also identified eltrombopag as a potential SARS-Cov-2 drug. Feng et 
al.’s studies suggested that eltrombopag bound not only to 3CL active site but also to the viral S-
protein and to human ACE2.41  This potential synergistic polypharmacy could be particularly 
beneficial.  
 Very little has been reported on the direct antiviral activity of eltrombopag. Recently, 
Vogel et al. reported direct inhibition of cytomegalovirus (CMV) by therapeutic doses of 
eltrombopag used to treat thrombocytopenia. 42 They showed that eltrombopag inhibits the late 
stages of the HCMV replication cycle and reduces virus titres by 1.8 × 104-fold at 10µM and by 
15-fold at 500 nM. They suggested the mode of action was iron chelation and showed that 
eltrombopag was synergistic with ganciclovir in preventing viral replication.  
 Eltrombopag has also been proposed as a potential drug against SARS-CoV-2 spike 
protein on the basis of predicted strong binding to a pocket in the fusion cores of S2 domain.41 
Eltrombopag was also identified as a high binding affinity to human angiotensin converting 
enzyme 2 (ACE2), the primary binding site for the spike protein. Their virtual screen also used 
Autodock Vina, but no subsequent MD simulation was used for the top hit compounds from the 
screen. SPR was used to assess the binding of the drug to Mpro. Figure 7 shows a LigPlot 
representation of the interactions of key functional groups in eltrombopag with protease active 
site residues. These are also listed in Supplementary Table 2 for reference. 
   
Figure 7. LigPlot (left) and hydrophobic Mpro protein surface representation (right) of the main 
interactions between Mpro and eltrombopag and Mpro. 
 
 Eltrombopag is of particular interest as a Mpro inhibitor lead because it is novel and is also 
a member of a large class of small molecular TPO receptor agonists that may also exhibit activity 
against the viral protease, and potentially the spike protein and human ACE2.43. However, given 
the clotting disorders that SAR-Cov-2 generates, the TPOR agonist activities would need to be 
minimized to prevent platelet enhancement, while retaining or enhancing the antiviral activities.  
Apart from the drugs discussed above, several other drugs in the list in Supplementary Table 
1 are of interest.  There are several other ergot derivatives with good predicted binding affinities 
to Mpro. Metergotamine  and dihydroergocristine were predicted to have DGbind of –29 and –24 
kcal/mol respectively. Other drugs with binding energies stronger than –25 kcal/mol include 
galicaftor (clinical trial for cystic fibrosis), rolitetracycline (broad spectrum antibiotic), disogluside 
(natural product from Dioscorea nipponica Makino that reduces liver chronic inflammation and 
fibrosis), zafirlukast (leukotriene receptor antagonist for asthma), diosmin (a natural flavone for 
treating venous disease), AZD-5991 (clinical trial  for relapsed or refractory haematologic 
malignancies), and ruzasvir (clinical trials for treatment of hepatitis C).  
Li et al. has reported predicted Mpro binding for galicaftor.44 The protease binding of 
rolitetracycline has been reported by Durdagi et al. and Gul et al.45, 46 Zhu and corkers measured 
the SARs-Cov-2 and Mpro inhibition of zafirlukast.47 The IC50 for Mpro was 24 µM and the EC50 
for the virus >20µM. The potential of the natural product diosmin as an antiviral agent targeting 
Mpro has also been reported in several recent computational studies.48-51 Chakraborti et al. reported 
the potential of ruzasvir as a drug against SARS-Cov-2, although no data were provided.52 These 
drugs and natural products merit assessment in SAR-Cov-2 assays and Mpro inhibition 
experiments. 
 
Conclusions 
Our virtual screening approach that applies Autodock Vina and MD simulation in tandem to 
calculate binding energies for repurposed drugs has identified 84 promising compounds for 
treating SARS-Cov2 infections. The screening was applied against the viral main protease Mpro 
(3CLpro). The top hits from out study consisted of a mixture of antiviral agents , natural products 
and drugs that were developed for other applications and that have other models of action. The 
prognostic value of our computational approach has been demonstrated by the fact that it identified 
a diverse range of drugs that have been reported in other computational studies or that exhibit 
useful SARS-Cov-2 antiviral effects in vitro. The antiviral drugs simeprevir, sofosbuvir, lopinavir, 
ritonavir and remdesivir exhibit strong antiviral properties and several in in clinical trial or use 
against SARS-Cov-2. These drugs have been identified as binding to Mpro also by numerous virtual 
screening studies and by in vitro assays. The more interesting and least studied lead drugs amongst 
our candidate list, bemcentinib, PC786, montelukast, ergotamine and mergocriptine, were 
predicted to have binding affinities equal to or greater than the antiviral drugs, and have also been 
shown to have in vitro antiviral activity against SARS-CoV-2. A few computational studies mostly 
using less rigorous methods than those we employed here, have also suggested that these drugs 
may bind to Mpro. 
 This high validation success rate strongly suggests that this type of virtual screening 
approach is capable of identifying compounds with potentially useful activity against SARS-CoV-
2 and, by analogy, other coronaviruses.  In particular, the 28 drugs for which no SARS-CoV-2 
activity has been yet reported may be of particular interest for in vitro screening. The results of the 
current drug repurposing study provides information that could be useful to identify additional 
candidate drugs for testing for use in the current pandemic, as well as a rational computational 
paradigm for identifying therapeutic agents for future viral pandemics. 
 
Materials and Methods 
Protein structure preparation and grid preparation 
The crystal structure of the COVID-19 Mpro (Figure 8) was downloaded from the RCSB PDB 
(http://www.rcsb.org; refcode 6Y2F).18  
 Figure 8. 3D structure of SARS-Cov-2 Mpro (PDB refcode 6Y2F) 
  
 Protein preparation and removal of non-essential and non-bridging water molecules for 
docking studies were performed using the UCSF Chimera package 
(https://www.cgl.ucsf.edu/chimera/). 53 AutoDock Tools (ADT) software was used to prepare the 
required files for Autodock Vina by assigning hydrogen polarities, calculating Gasteiger charges 
to protein structures and converting protein structures from the .pdb file format to .pdbqt format.54. 
The surface area of the 3CLPro binding pocket is 335 Å2, volume – 364.101 Å3.55 
Screening databases 
Drugs database were downloaded from the DrugBank database (Wishart et al., 2018) and 
CHEMBL database (FDA approved) (Gaulton et al., 2017). A total of 8773 and 13,308 drugs were 
retrieved from Drugbank and CHEMBL database, respectively. The drugs were downloaded in sdf 
format and converted to .pdbqt format using Raccoon (Forli et al., 2016). 
Docking Methodology 
Small molecule ligand structures were docked against protein structure using the AutoDock Vina 
(version 1.1.3) package.54 AutoDock Vina employs gradient-based conformational search 
approach and an energy-based empirical scoring function. AutoDock Vina is also flexible, easily 
scripted, extensively validated in many published studies with a variety of proteins and ligands 
and takes advantage of large multi-CPU or -GPU machines to run many calculations in parallel. 
The code has also been employed very successfully to dock millions of small molecule drug 
candidates into a series of protein targets to discover new potent drug leads. The package includes 
useful scripts for generating modified .pdb files required for grid calculations and for setting up 
the grid calculations around each protein automatically. The software requires the removal of 
hydrogens, addition of polar hydrogens, setting of the correct atom types, and calculation of atom 
charges compatible with the AutoGrid code. The algorithm generates a grid around each protein 
and calculates the interaction energy of a probe noble gas atom at each grid position outside and 
within internal cavities of the protein. The grid resolution was set to 1 Å, the maximum number of 
binding modes to output was fixed at 10, and the exhaustiveness level (controlling the number of 
independent runs performed) was set at 8. The docking employed a genetic algorithm to optimize 
the binding conformations of the ligands during docking to the protease site. Drugs were docked 
individually to the active site of Mpro (3CLPro, refcode 6Y2F) with the grid coordinates (grid 
centre) and grid boxes of appropriate sizes generated by the bash script vina_screen.sh 
(Supplementary Information). The top scored compounds were identified with a python script 
script1.py (Supplementary Information) and subjected to molecular dynamic simulation. The 
docked structures were analysed using UCSF Chimera 53 and LigPlot+ software56 to illustrate 
hydrogen-bond and hydrophobic interactions. A total of fifty top compounds selected from each 
of the Drugbank and CHEMBL compounds. Sixteen compounds were common to both database 
top hits. Molecular dynamics studies were conducted on the unique set of eighty-four compounds 
from both sets.  
Molecular Dynamics Simulation 
The top screened compound complexes with protease were minimized with CHARMm force field. 
The topology files of the ligands were prepared from Swissparam (http://www.swissparam.ch/) 57 
and minimized in Gromacs2020 (http://www.gromacs.org/).58. Docked complexes of ligands and 
COVID-19 Mpro protein were used as starting geometries for MD simulations. Simulations were 
carried out using the GPU accelerated version of the program with the CHARMm force field I 
periodic boundary conditions in ORACLE server. Docked complexes were immersed in a 
truncated octahedron box of TIP3P water molecules. The solvated box was further neutralized with 
Na+ or Cl− counter ions using the tleap program. Particle Mesh Ewald (PME) was employed to 
calculate the long-range electrostatic interactions. The cut-off distance for the long-range van der 
Waals (VDW) energy term was 12.0 Å.  The whole system was minimized without any restraint. 
The above steps applied 2500 cycles of steepest descent minimization followed by 5000 cycles of 
conjugate gradient minimization. After system optimization, the MD simulations was initiated by 
gradually heating each system in the NVT ensemble from 0 to 300 K for 50 ps using a Langevin 
thermostat with a coupling coefficient of 1.0/ps and with a force constant of 2.0 kcal/mol·Å2 on 
the complex.  Finally, a production run of 20 ns of MD simulation was performed under a constant 
temperature of 300 K in the NPT ensemble with periodic boundary conditions for each system. 
During the MD procedure, the SHAKE algorithm was applied for the constraint of all covalent 
bonds involving hydrogen atoms. The time step was set to 2 fs. The structural stability of the 
complex was monitored by the RMSD and RMSF values of the backbone atoms of the entire 
protein. Calculations were also performed for up to 100 ns on few compounds to ensure that 20ns 
is sufficiently long for convergence. Duplicate production runs starting with different random 
seeds were also run to allow estimates of binding energy uncertainties to be determined. 
 The binding free energies of the protein‐protein complexes were evaluated in two ways. 
The traditional method is to calculate the energies of solvated SARS-Cov-2 protease and small 
molecule ligands and that of the bound complex and derive the binding energy by subtraction. 
ΔG (binding, aq) = ΔG (complex, aq) – (ΔG (protein, aq) + ΔG (ligand, aq)  (1) 
We also calculated binding energies using the molecular mechanics Poisson Boltzmann surface 
area (MM/PBSA) tool in GROMACS that is derived from the nonbonded interaction energies of 
the complex. The method is also widely used method for binding free energy calculations.  
 MMPBSA calculations were conducted by GMXPBSA 2.159 a suite based on Bash/Perl 
scripts for streamlining MM/PBSA calculations on structural ensembles derived from GROMACS 
trajectories and to automatically calculate binding free energies for protein–protein or ligand–
protein. GMXPBSA 2.1 calculates diverse MM/PBSA energy contributions from molecular 
mechanics (MM) and electrostatic contribution to solvation (PB) and non-polar contribution to 
solvation (SA). This tool combines the capability of MD simulations (GROMACS) and the 
Poisson–Boltzmann equation (APBS) for calculating solvation energy (Baker et., 2001). The 
g_mmpbsa tool in GROMACS was used after molecular dynamics simulations, the output files 
obtained were used to post-process binding free energies by the single-trajectory MMPBSA 
method. In the current study we considered 100 frames at equal distance from 20ns trajectory files.  
 Specifically, for a non-covalent binding interaction in the aqueous phase the binding free 
energy, ΔG (bind,aq), is: – 
ΔG (bind,aqu) = ΔG (bind,vac) + ΔG (bind,solv)    (2) 
where ΔG (bind,vac) is the binding free energy in vacuum, and ΔG(bind,solv) is the solvation free 
energy change upon binding: – 
ΔG (bind,solv) = ΔG (R:L, solv) - ΔG (R,solv) - ΔG (L,solv)   (3) 
where ΔG (R:L,solv), ΔG (R,solv) and ΔG (L,solv) are solvation free energies of complex, 
receptor and ligand, respectively. 
While this manuscript was in preparation, Guterres and Im showed how substantial improvement 
in protein-ligand docking results could be achieved using high-throughput MD simulations.60 As 
with our study, they also employed AutoDock Vina for docking, followed by MD simulation using 
CHARMM. The MD parameters they advocated were very similar to those used in our study. 
Proteins were solvated in a box of TIP3P water molecules extending 10 Å beyond the proteins and 
the particle-mesh Ewald method was used for electrostatic interactions. Nonbonded interactions 
over 10 and 12 Å were truncated. Their systems were minimized for 5000 steps using the steepest 
descent method followed by 1 ns equilibration with an NVT setting. For each protein-ligand 
complex, they ran 3 × 100 ns production runs from the same initial structure using different initial 
velocity random seeds and an integration step size of 2 fs. Over 56 protein targets (of 7 different 
protein classes) and 560 ligands this show 22% improvement in the area under receiver operating 
characteristics curve, from an initial value of 0.68 using AutoDock Vina alone to a final value of 
0.83 when the Vina results were refined by MD. 
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Supplementary information 
Table S1. Binding energies and published SARS-Cov-2 data for 84 top ranked small molecule ligands 
 Name 
ChEMBL (C)) 
or Drugbank 
(D) ID 
ΔGMMPBSA 
kcal/mol 
SARS-Cov-2 data 
1 Bemcentinib  C 3809489 -33.9 
Phase 2 clinical trial,1 ED50 0.1 (Huh7.5), 0.47 (Vero), 2.1 
(Calu3) µM,2 predicted 2’-O-methyltransferase nsp16/nsp10 
complex binding3 
2 PC786  C 4291143 -33.0 Predicted spike glycoprotein,4 Mpro, and ACE2 binding5 
3 Montelukast  C 787 -32.6 
Significant reduction in SARS-CoV-2 infection in elderly 
asthmatic patients treated with MK.6 Several predicted Mpro 
binding studies e.g.6, 7  
4 Ergotamine  C 442 -31.6 Several predicted Mpro binding studies e.g.8-10 
5 Simeprevir D06290 -31.5 
In vitro EC50 4.08 μM, and many predicted Mpro binding studies 
e.g.11, many predicted Mpro binding studies e.g.12-14, predicted 
RdRp binding15, 16   
6 Sofosbuvir D08934 -31.0 In vitro EC50 values of 6.2 and 9.5 μM.
17 Predicted RdRp18, 19 
binding 
7 Lopinavir D01601 -30.7 
In vitro EC50 5.73 µM,20 Multiple single agent and combination 
human trials e.g.21, 22. In vitro EC50 26.63 μM.23 Predicted Mpro 
binding24-26 
8 Ritonavir D00503 -30.2 
In vitro EC50 8.63 µM,20 Multiple single agent and combination 
human trials e.g.21, 27 Predicted Mpro 26 helicase and RdRp 
binding28 
9 Mergocriptine  C2105887 -30.1 Predicted 2′-O-ribose methyltransferase29 binding 
10 Remdesivir D14761 -29.9 Multiple human trials e.g.
30, 31, in vitro EC50 23.15 μM,23 
predicted Mpro 32 and RdRp33 binding 
11 Metergotamine C2106428 -29.1 Predicted 2′-O-ribose methyltransferase29 binding 
 Name 
ChEMBL (C)) 
or Drugbank 
(D) ID 
ΔGMMPBSA 
kcal/mol 
SARS-Cov-2 data 
12 Galicaftor D14894 -28.4 Predicted Mpro binding34 
13 Eltrombopag  C461101 -28.2 Predicted spike35 and RdRp8 binding 
14 Saquinavir  C114 -27.9 In vitro EC50 8.83 µM,
20 predicted ACE2, Mpro,10 and RdRp36 
binding37 
15 Rolitetracycline C 1237046 -27.6 Predicted Mpro 38 and spike39 binding 
16 Disogluside C395414 -27.3 Predicted Mpro 29 binding 
17 Zafirlukast D00549 -26.7 Predicted spike,
10 Mpro,40 and 2′-O-ribose methyltransferase41 
binding 
18 Diosmin D08995 -25.8 Predicted Mpro 42, 43 binding 
19 AZD-5991 D14792 -25.2 … 
20 Ruzasvir C 3833385 -25.1 Predicted Mpro 44 and RdRp16 binding 
21 Rebastinib C1738757 -24.3 Predicted 2'-O-ribose methyltransferase nsp16 binding29 
22 RSV-604 D15197 -24.3 … 
23 Eravacycline D12329 -24.2 Predicted Mpro 45, 46 binding 
24 Lifitegrast C2048028 -24.1 Predicted nsp16/nsp10 complex3 and RdRp16 binding 
25 10-Deoxymethynolide D07703 -24.1 … 
26 Ledipasvir D09027 -23.8 Predicted Mpro binding47 
27 Deldeprevir C3040582 -23.8 Predicted Mpro binding13 
28 Rifamycin D11753 -23.8 … 
29 Ethoxazorutoside C 2106047 -23.8 … 
30 Dihydroergocristine C601773 -23.8 Predicted Mpro 47 binding 
31 Gedatolisib C592445 -23.8 … 
32 Lorecivivint D14883 -23.8 Predicted Mpro 42 and spike5 binding 
33 MK-6325  C4297304 -23.6 … 
34 Laniquidar  C539378 -23.1 Predicted RdRp48 and spike49 binding 
35 Tirabrutinib C 4071161 -22.9 EC50 >10µM in SARS-CoV-2-Nluc neutralization assay50 
36 3-(2-aminoquinazolin-6-yl)-4-methyl-N-[3- D06925 -22.9 
… 
 Name 
ChEMBL (C)) 
or Drugbank 
(D) ID 
ΔGMMPBSA 
kcal/mol 
SARS-Cov-2 data 
(trifluoromethyl)phenyl]benzamide 
37 Ensartinib D14860 -22.8 … 
38 Anacetrapib C1800807 -22.4 … 
39 Pazinaclone  C2107504 -22.3 Predicted Mpro binding51 
40 BMS-986142 D15291 -22.2 … 
41 Phthalocyanine D12983 -22.2 Predicted nsp1,
52 Mpro,34 spike,49 nsp1,52 and 2′-O-
methyltransferase3 binding 
42 Umbralisib C3948730 -21.9 … 
43 DNK333  C105060 -21.9 … 
44 Midostaurin C608533 -21.7 Predicted Mpro binding.40 
45 Umifenovir D13609 -21.6 
Multiple clinical trials only show higher –ve rate of PCR on day 
14 in adult COVID‐19 patients.53 Shorten the viral shedding 
interval.54  Predicted Mpro binding.55 
46 Lumacaftor D09280 -21.5 Predicted Mpro 47, 48, 56 and RdRp57 binding 
47 TU-100 D12467 -21.3 … 
48 Triamcinolone furetonide C2105791 -21.2 … 
49 Zoliflodacin C3544978 -21.2 Predicted Mpro 58 and PLpro48 binding 
50 KPT-9274  C4297467 -20.9 … 
51 Atazanavir D01072 -20.8 Inhibits SARS-CoV-2 replication, predicted M
pro 59 and 
helicase60 binding 
52 Mitratapide  C2104975 -20.8 Predicted 2'-O-ribose methyl-transferase nsp16 binding29 
53 Tarloxotinib D14944 -20.5 … 
54 Spergualin C1765508 -20.5 … 
55 Moxidectin D11431 -20.5 … 
56 PRI-724 D15034 -20.0 … 
57 
2-[3-(methyl[1-(2-naphthoyl)piperidin-
4-yl] amino}carbonyl)-2-naphthyl]-1-
(1-naphthyl)-2-oxoethyl phosphonic 
D04016 -19.8 
… 
 Name 
ChEMBL (C)) 
or Drugbank 
(D) ID 
ΔGMMPBSA 
kcal/mol 
SARS-Cov-2 data 
acid 
58 ASP-4058 D11819 -19.8 … 
59 Beclabuvir DB12225 -19.7 Predicted RdRp15 and Mpro 61 binding 
60 Ubrogepant C2364638 -19.5 Predicted to disrupt spike-ACE2 interaction62 
61 Dihydroergotamine D00320 -19.5 Predicted Mpro 8, 9 and 2′-O-ribose methyltransferase41 binding  
62 Lifirafenib C 4209157 -19.3 Predicted spike48 and nsp10– nsp16 complex3 binding 
63 Golvatinib D11977 -18.8 Predicted Mpro 48 and RdRp36 binding 
64 Tirilazad D13050 -18.6 Predicted Mpro 25, 61 and nsp152 binding 
65 
4-[(10s,14s,18s)-18-(2-amino-2-
oxoethyl)-14-(1-naphthylmethyl)-
8,17,20-trioxo-7,16,19-triaza 
spiro[5.14]icos-11-en-10-
yl]benzylphosphonic acid 
D03276  -18.6 
… 
66 Etamocycline  C3989417 -16.1  
67 Quarfloxin  C3989407 -15.9 Predicted spike,49 PLpro48 and Mpro 37   
68 
2'-(4-dimethylamino-phenyl)-5-(4-
methyl-1-piperazinyl)-2,5'-bi-
benzimidazole 
D04011  -15.7 
… 
69 Dihydrostreptomycin C 1950576 -15.6 Predicted nsp3 and nsp10– nsp16 complex binding63 
70 Rimegepant C2178422 -15.6 … 
71 Bezitramide C2104149 -15.4 … 
72 Flutroline C57241 -15.3 Predicted 2'-O-ribose methyltransferase nsp16 binding29 
73 Carfilzomib D08889 -15.2 Predicted Mpro binding45 
74 IPI-549  C3984425 -15.0 … 
75 Milademetan C4292264 -14.6 Predicted Mpro binding45 
76 Nemiralisib C2216859 -14.4 Predicted Mpro binding64 
77 Amrubicin  C1186894 -14.3 Predicted Mpro 65 binding 
78 Genz-10850 D04289 -13.1 Predicted nsp12 binding66 
 Name 
ChEMBL (C)) 
or Drugbank 
(D) ID 
ΔGMMPBSA 
kcal/mol 
SARS-Cov-2 data 
79 Penimepicycline C 3833378 -12.9 Predicted to Mpro and spike38 binding 
80 Tipifarnib  C289228 -12.6 … 
81 MK3207  C1910936 -12.1 Predicted M
pro,67 PLpro,68 2'-O-ribose methyl-transferase nsp1629 
binding 
82 Naldemedine C2105791 -12.1 Predicted Mpro 40 and spike RBD 69 binding 
83 Tariquidar D06240 -12.0 … 
84 Netupitant C206253 -11.9 Predicted RdRp binding 14and Mpro 40 
 
  
Table S2. Binding interactions with Mpro binding site for top 10 ranked drugs. 
ID Drug Interacting Residues H-Bond 
CHEMBL7835 
 
Bemcitinib THR26, LEU27, HIS41, ASN142, GLY143, SER144, CYS145, HIS164, 
MET165, GLU166, LEU167, PRO168, VAL186, ASP187, ARG188, GLN189, 
THR190, ALA191, GLN192 
VAL186 (O-N8) 2.70 
ARG188(O-N8) 2.65 
GLN192 (NE2 -N7)   3.27  
CHEMBL442 
 
Ergotamine THR25, LEU27, HIS41, PHE140, LEU141, ASN142, GLY143, SER144, 
CYS145, HIS163, HIS164, MET165, GLU166, HIS172, VAL186, ASP187, 
ARG188, GLN189, THR190, GLN192 
GLY143(N-O4) 2.68 
HIS164 (O-O5) 3.29 
MET165(SD-C12) 3.18 
DB01601 
 
Lopinavir  THR26, HIS41, MET49, PHE140, LEU141, ASN142, CYS145, HIS163, 
HIS164, MET165, GLU166, HIS172, VAL186, ASP187, ARG188, GLN189, 
THR190, GLN192 
ASN142 (OD1-O2) 2.59 
 
CHEMBL4958 
 
Mergocriptine HIS41, CYS44, MET49, ASN142, GLY143, SER144, CYS145, HIS163, 
HIS164, MET165, GLU166, LEU167, PRO168, VAL186, ASP187, ARG188, 
GLN189, THR190, GLN192 
CYS145(SG-O3) 3.22 
THR190 (O-N5) 3.01 
CHEMBL4291143 PC-786 THR25, THR26, HIS41,  CYS44, MET49, TYR54, PHE140, LEU141, 
ASN142, GLY143, SER144, CYS145, HIS163, HIS164, MET165, GLU166,  
HIS172, ASP187, ARG188, GLN189 
GLY143(N-O4) 2.67 
SER144(OG-F1) 2.59 
SER144(N-O4) 2.85 
CYS145 (SG-F1) 3.01 
CYS145 (N-)4) 3.06 
DB14761 Remdesivir HIS41, MET49, PHE140, LEU141, ASN142, GLY143, SER144, CYS145, 
HIS163, HIS164, MET165, GLU166, HIS172, VAL186, ASP187, ARG188, 
THR190, GLN192 
PHE140(O-N5) 2.98 
SER144(OG-N6) 3.14 
HIS163(NE2-N6) 3.01 
HIS164(O-O4) 2.67 
 
ID Drug Interacting Residues H-Bond 
DB00503 
 
Ritonavir THR25, THR26, LEU27, HIS41, CYS44, THR45, SER46, MET47, PHE140, 
LEU141, ASN142, GLY143, SER144, CYS145, HIS163, HIS164, MET165, 
GLU166, LEU167, PRO168, HIS172, VAL186, ARG188, GLN189, THR190, 
GLN192 
CYS145(SG-O3) 3.03 
HIS164(O-O3) 2.88 
DB06290 Simeprevir HIS41, CYS44, MET49, TYR54, PHE140, LEU141, ASN142, GLY143, 
SER144, CYS145, HIS163, HIS164, MET165, GLU166, LEU167, PRO168, 
THR169, GLY170, HIS172, VAL186, ARG188, GLN189, THR190, GLN192 
HIS163(NE2-O4) 3.09 
HIS164(O-N3) 3.18 
CYS145(O-HO) 3.34 
DB08934 Sofosbuvir HIS41, MET49, TYR54, PHE140, LEU141, ASN142, GLY143, SER144, 
CYS145, HIS163, HIS164, MET165, GLU166, LEU167, PRO168, HIS172, 
VAL186, ARG188, GLN189, THR190, GLN192, ALA193 
SER144(OG-O9) 3.09 
GLU166(N-O6) 3.28 
 
CHEMBL4499 
 
Montelukast THR25, THR26, LEU27, HIS41, MET49, TYR54, PHE140, LEU141, 
ASN142, GLY143, SER144, CYS145, HIS163, HIS164, MET165, GLU166, 
LEU167, PRO168, ASP187, ARG188, GLN189, THR190, GLN192 
SER144 (N-O3) 2.95 
SER144 (OG-O3) 2.89 
CYS145 (N-O3) 3.17 
 
 
 
 
Scripts: 
1)Conf.txt 
receptor = 6Y2F.pdbqt 
center_x=  9.245 
center_y=  -0.788 
center_z = 18.371 
size_x = 50 
size_y = 50 
size_z = 50 
num_modes = 10 
exhaustiveness = 50 
 
2)vina_screen.sh 
#! /bin/bash 
for f in CHEMBL*.pdbqt; do 
    b=`basename $f .pdbqt` 
    echo Processing ligand $b 
mkdir -p $b 
    vina --config conf.txt --cpu 50 --ligand $f --out $[b]/out.pdbqt --log $[b]/log.txt 
done 
 
3)Script1.py 
 
#! /usr/bin/env python 
import sys 
import glob 
def doit(n): 
file_names = glob.glob('*/*.pdbqt') 
    everything = [] 
    failures = [] 
    print 'Found', len(file_names), 'pdbqt files' 
    for file_name in file_names: 
        file = open(file_name) 
        lines = file.readlines() 
file.close() 
        try: 
            line = lines[1] 
            result = float(line.split(':')[1].split()[0]) 
everything.append([result, file_name]) 
        except: 
failures.append(file_name) 
everything.sort(lambda x,y: cmp(x[0], y[0])) 
    part = everything[:n] 
    for p in part: 
        print p[1], 
    print 
    if len(failures) > 0: 
        print 'WARNING:', len(failures), 'pdbqt files could not be processed' 
if __name__ == '__main__': 
doit(int(sys.argv[1])) 
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